WO2009103319A3 - Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases - Google Patents

Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases Download PDF

Info

Publication number
WO2009103319A3
WO2009103319A3 PCT/EP2008/008267 EP2008008267W WO2009103319A3 WO 2009103319 A3 WO2009103319 A3 WO 2009103319A3 EP 2008008267 W EP2008008267 W EP 2008008267W WO 2009103319 A3 WO2009103319 A3 WO 2009103319A3
Authority
WO
WIPO (PCT)
Prior art keywords
ezrin
peroxiredoxin
serpin
heat shock
autoantigens
Prior art date
Application number
PCT/EP2008/008267
Other languages
French (fr)
Other versions
WO2009103319A2 (en
Inventor
Jörg C. PRINZ
Petra Besgen
Paul Trommler
Original Assignee
Ludwig-Maximilians-Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig-Maximilians-Universität filed Critical Ludwig-Maximilians-Universität
Priority to US12/918,459 priority Critical patent/US20110033479A1/en
Priority to EP08872644A priority patent/EP2278990A2/en
Publication of WO2009103319A2 publication Critical patent/WO2009103319A2/en
Publication of WO2009103319A3 publication Critical patent/WO2009103319A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01015—Peroxiredoxin (1.11.1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Abstract

The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein β1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragments, variants, or epitopes thereof and/or mixtures of at least two of the proteins and/or peptides as diagnostic tool for the detection of streptococcal driven conditions or as therapeutical agent for the treatment of streptococcal driven conditions.
PCT/EP2008/008267 2008-02-19 2008-09-29 Proteins ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis vulgaris and poststreptococcal diseases WO2009103319A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/918,459 US20110033479A1 (en) 2008-02-19 2008-09-29 Proteins ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis vulgaris and poststreptococcal diseases
EP08872644A EP2278990A2 (en) 2008-02-19 2008-09-29 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2008/001283 WO2009103312A1 (en) 2008-02-19 2008-02-19 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
EPPCT/EP2008/001283 2008-02-19

Publications (2)

Publication Number Publication Date
WO2009103319A2 WO2009103319A2 (en) 2009-08-27
WO2009103319A3 true WO2009103319A3 (en) 2010-01-21

Family

ID=39247120

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2008/001283 WO2009103312A1 (en) 2008-02-19 2008-02-19 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
PCT/EP2008/008267 WO2009103319A2 (en) 2008-02-19 2008-09-29 Proteins ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis vulgaris and poststreptococcal diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/001283 WO2009103312A1 (en) 2008-02-19 2008-02-19 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases

Country Status (2)

Country Link
US (1) US20110033479A1 (en)
WO (2) WO2009103312A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101147006B1 (en) * 2010-03-18 2012-05-22 전남대학교산학협력단 C-termnal truncated peroxiredoxin ? and a composition containg the same for preventing or treating apoptosis
EP3343226B1 (en) * 2010-09-21 2022-07-27 Proteomics International Pty Ltd Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions
EP3112375A1 (en) * 2015-07-03 2017-01-04 Ludwig-Maximilians-Universität München Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris
CN116925219B (en) * 2023-09-19 2023-12-08 北京索莱宝科技有限公司 Antibody of small heat shock protein HSPB1, hybridoma cell strain and application thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034638A1 (en) * 1997-02-06 1998-08-13 Dana-Farber Cancer Institute Maspin inhibition of tpa activity
US5905023A (en) * 1991-02-28 1999-05-18 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppressing activity
WO1999047150A2 (en) * 1998-03-18 1999-09-23 Institut Curie A pharmaceutical composition containing ezrin mutated on tyrosine 353
US5976810A (en) * 1994-09-08 1999-11-02 Hoechst Pharmaceuticals & Chemicals K.K. Method of detecting autoantibody present in the serum of rheumatic
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
US20020086019A1 (en) * 2000-06-20 2002-07-04 Eckard Wolf Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
US20040105860A1 (en) * 2002-08-01 2004-06-03 Losordo Douglas W. Cell modulation using a cytoskeletal protein
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
WO2005014637A1 (en) * 2003-08-12 2005-02-17 Istituto Superiore di Sanità Apoptosis inhibitors
WO2005040805A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein masp as a marker for breast cancer
JP2005255542A (en) * 2004-03-09 2005-09-22 Techno Network Shikoku Co Ltd Method for controlling formation and suppressing destruction of cartilage and bone tissue with maspin
EP1619501A1 (en) * 2004-07-22 2006-01-25 Schering AG Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
WO2006037606A2 (en) * 2004-10-04 2006-04-13 Switch Biotech Aktiengesellschaft Wound dressing compositions, especially for delivery of protease inhibitors
WO2007006858A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
WO2007060440A2 (en) * 2005-11-23 2007-05-31 Regent Research L.L.P. The use of peptides in anti-ulcer therapy
WO2007095583A2 (en) * 2006-02-14 2007-08-23 Children's Memorial Research Center Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955089A (en) * 1993-04-20 1999-09-21 Uab Research Foundation Strain selection of pneumococcal surface proteins

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905023A (en) * 1991-02-28 1999-05-18 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppressing activity
US5976810A (en) * 1994-09-08 1999-11-02 Hoechst Pharmaceuticals & Chemicals K.K. Method of detecting autoantibody present in the serum of rheumatic
WO1998034638A1 (en) * 1997-02-06 1998-08-13 Dana-Farber Cancer Institute Maspin inhibition of tpa activity
WO1999047150A2 (en) * 1998-03-18 1999-09-23 Institut Curie A pharmaceutical composition containing ezrin mutated on tyrosine 353
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
US20020086019A1 (en) * 2000-06-20 2002-07-04 Eckard Wolf Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
US20040105860A1 (en) * 2002-08-01 2004-06-03 Losordo Douglas W. Cell modulation using a cytoskeletal protein
WO2005014637A1 (en) * 2003-08-12 2005-02-17 Istituto Superiore di Sanità Apoptosis inhibitors
WO2005040805A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein masp as a marker for breast cancer
JP2005255542A (en) * 2004-03-09 2005-09-22 Techno Network Shikoku Co Ltd Method for controlling formation and suppressing destruction of cartilage and bone tissue with maspin
EP1619501A1 (en) * 2004-07-22 2006-01-25 Schering AG Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
WO2006037606A2 (en) * 2004-10-04 2006-04-13 Switch Biotech Aktiengesellschaft Wound dressing compositions, especially for delivery of protease inhibitors
WO2007006858A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
WO2007060440A2 (en) * 2005-11-23 2007-05-31 Regent Research L.L.P. The use of peptides in anti-ulcer therapy
WO2007095583A2 (en) * 2006-02-14 2007-08-23 Children's Memorial Research Center Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CYWES C ET AL: "Group A Streptococcus tissue invasion by CD44-mediated cell signalling", NATURE, vol. 414, no. 6864, 6 December 2001 (2001-12-06), GB, pages 648 - 652, XP002191019, ISSN: 0028-0836 *
DATABASE WPI Week 200569, Derwent World Patents Index; AN 2005-668822, XP002556710 *
HOE NANCY P ET AL: "Insight into the molecular basis of pathogen abundance: Group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 11, 28 May 2002 (2002-05-28), pages 7646 - 7651, XP002289162, ISSN: 0027-8424 *
VAN GENT DIANA ET AL: "Serpins: structure, function and molecular evolution.", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY NOV 2003, vol. 35, no. 11, November 2003 (2003-11-01), pages 1536 - 1547, XP002556711, ISSN: 1357-2725 *

Also Published As

Publication number Publication date
US20110033479A1 (en) 2011-02-10
WO2009103312A1 (en) 2009-08-27
WO2009103319A2 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
EP2336174A3 (en) Human monoclonal antibodies against Hendra and Nipah viruses
BRPI0513798A (en) anti-cd154 antibodies
WO2008105797A3 (en) Polynucleotides encoding novel pcsk9 variants
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
WO2011036445A3 (en) Polypeptides and uses thereof
WO2010065824A3 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2006081826A3 (en) Survivin peptide vaccine
WO2007092640A3 (en) Antibodies that bind par-2
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2007109370A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
WO2005016127A3 (en) Prion-specific peptide reagents
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2009079481A3 (en) Methods to diagnose and immunize against the virus causing human merkel cell carcinoma
WO2009103319A3 (en) Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2005016132A3 (en) Diagnostics for sars virus
ATE506957T1 (en) PROPHYLACTIC/THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
WO2004094476A3 (en) Compositions and methods relating to stop-1
HK1145397A1 (en) Peptides derived from plasminogen activator inhibitor-1 and uses thereof
WO2014053110A3 (en) Peptides for the treatment and early diagnosis of alzheimer's disease and other tauopathies
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders
WO2007052154A3 (en) Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08872644

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6136/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008872644

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12918459

Country of ref document: US